Private Advisor Group’s Autolus Therapeutics AUTL Stock Holding History

Private Advisor Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.6K	Buy	+14,220	New	+$27.1K	﹤0.01%	3084

Other funds holding AUTL

Syncona Portfolio St Peter Port, Guernsey $32.3M AUM 51.22% 1-Year Est. Return

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return

Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Private Advisor Group's AUTL Position: Q3 2026 in Review

Private Advisor Group opened a new position in Autolus Therapeutics (AUTL) in Q3 2026: 14,220 shares worth $27.6K. The stake represents ﹤0.01% of the portfolio and ranks #3084 among its holdings.

38 funds tracked by Wall St. Rank hold AUTL as of Q3 2026.

Private Advisor Group held 14,220 shares of Autolus Therapeutics worth $27.6K as of Q3 2026.
Autolus Therapeutics was a new Private Advisor Group position in Q3 2026.
Autolus Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q3 2026, its #3084 holding.
38 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2026.

Based on Private Advisor Group's 13F filing for Q3 2026, filed 10 Nov 2026.